Chiara Bonzano
Increasing resistance to antimicrobial agents has contributed to an elevated risk of complications of infectious keratitis. Corneal collagen cross-linking (CXL) has been widely adopted for the management of keratoconus and post-refractive surgery corneal ectasia. It has recently been introduced as an option for treating keratitis due to multidrug resistant organisms. The purpose of this review is to discuss the rationale, safety, and evidence for CXL in infectious keratitis and its possible effect on ocular surface inflammation. Published data show that CXL is effective and safe as an adjunct to antibiotic treatment in selected cases of bacterial keratitis. The benefit of CXL probably varies according to the etiology of the infection.
Shotgun sequencing can be used as a diagnostic tool in microbial keratitis samples. This diagnostic method expands the available tests to diagnose eye infections and could be clinically significant in culture negative samples.
Understanding the cascade of events involved in the nerve growth factor-driven corneal wound healing process is clinically meaningful for the clinician. AS-OCT is an effective tool for systematic anterior segment imaging, allowing the detailed detection of the front-to-back layered corneal structure for quantitative analysis and monitoring of the healing process.
Dry eye disease (DED) is a multifactorial disease that results in symptoms of discomfort, visual disturbance, and damage to the ocular surface. Because chronic inflammation plays an important role in DED, treatment with topical corticosteroids has been demonstrated to ameliorate the signs and symptoms of the disease. Although these agents have proven short-term efficacy, their long-term use may cause intraocular pressure elevation and cataract progression. A carefully review of the different studies shows that differences between corticosteroids may exist regarding the incidence of side effects and evidence of efficacy in DED patients.
Roma, 4 dic. - La cheratite da acanthamoeba è un'infezione oculare parassitaria grave e progressiva, caratterizzata da riduzione della acuità visiva, rossore oculare, estrema sensibilità alla luce e dolore oculare, in alcuni casi lancinante. Se non trattata, progredisce inesorabilmente. Solo in una piccola percentuale di casi (5%) si ottiene una risoluzione senza perdita significativa della capacità visiva. Nei rimanenti casi è necessario eseguire un trapianto corneale per la rimozione dell’infezione o per il ripristino di una qualità di visione accettabile; 1 paziente su 5 subisce la asportazione dell'occhio. La malattia colpisce prevalentemente i giovani, molti dei quali sperimentano un sostanziale e permanente deterioramento della qualità della vita. Di fronte ad una malattia così subdola, si è mobilitato un gruppo di esperti, opinion leader e pazienti che, attraverso momenti di confronto, è giunto alla formalizzazione e sottoscrizione di un Manifesto Sociale, in cui sono condensati gli aspetti principali riguardanti la malattia e le priorità di intervento per farvi fronte.
Il documento è stato presentato in occasione del Dialogue Meeting tenutosi oggi a Roma, a Palazzo Sturzo, sul tema 'Conoscere e riconoscere la cheratite da acanthamoeba', evento organizzato in collaborazione con l’Alleanza per l’Equità di Accesso alle Cure per le Malattie Oculari.
Of key importance in this Guide is to provide an overview of existing evidence on glaucoma surgery and specifically on recent innovations and novel devices, but also to set standards in surgical design and reporting for future studies on glaucoma surgical innovation. Therefore, the decision was made to issue this Guide on Glaucoma Surgery in order to help clinicians to make appropriate decisions for their patients and also to provide the framework and guidance for researchers to improve the quality of evidence in future studies. Ultimately this Guide will support better Glaucoma Care in accordance with EGS's Vision and Mission.
To investigate the demographic and corneal factors associated with the occurrence of delayed reepithelialization (DRE) after epithelium-off crosslinking (epi-off CXL).
